Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3894-3900

  Watson, Patrice ^a   Lieberman, Rita ^a   Snyder, Carrie ^a   Clark, Vanessa J ^a   Lynch, Henry T ^a   Holt, Jeffrey T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; MONOCLONAL ANTIBODY;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; DIAGNOSTIC ACCURACY; FAMILIAL CANCER; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TISSUE TRUNCATION TEST; TUMOR SUPPRESSOR GENE; BIOPSY; BREAST TUMOR; FEMALE; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

BIOPSY; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENES, BRCA2; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION;

EID: 69849115528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.5211     Document Type: Article

References (23)

1. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 10:789-799, 2004
2. Lancaster JM, Wooster R, Mangion J, et al: BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13:238-240, 1996
3. Kwiatkowska E, Teresiak M, Breborowicz D, et al: Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 98:943-945, 2002
4. Collins N, McManus R, Wooster R: Consistent loss of the wildtype allele in families from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10:1673-1675, 1995
5. Osorio A, De la Hoya M, Rodriguez-Lopez R: Loss of heterozygosity at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 99:305-309, 2002
6. Narod SA, Offit K: Prevention and management of hereditary breast cancer. J Clin Oncol 23:1656-1663, 2005
7. Vink GR, van Asperen CJ, Devilee P, et al: Unclassified variants in disease-causing genes: Non-uniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet 13:525-527, 2005
8. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
9. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222-226, 2005
10. King MC, Marks JH, Mandell JB: The New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003
11. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
12. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
13. Simchoni S, Friedman E, Kaufmann B: Familial clustering of site specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A 103: 3770-3774, 2006
14. Jensen RA, Page DL, Holt JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci U S A 91:9257-9261, 1994
15. Roest PA, Roberts RG, Sugino S, et al: Protein truncation test (PTT) for rapid detection of translation-terminating mutations Hum Mol Genet 2:1719-1721, 1993
16. Mazoyer S, Dunning AM, Serova O, et al: A polymorphic stop codon in BRCA2. Nat Genet 14: 253-254, 1996
17. Walsh T, Casadie S, Coats KH, et al: Spectrum of mutations in BRCA1, BRCA2 CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379-1388, 2006
18. Kuzmiak HA, Mauqat LE: Applying nonsensemediated mRNA decay research to the clinic: Progress and challenges. Trends Mol Med 12:306-316, 2006
19. Ware MD, DeSliva D, Sinilnikova OM, et al: Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene. Oncogene 25:323-328, 2006
20. Chen J, Silver DP, Walpia D, et al: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2:317-328, 1998
21. Vaz FH, Machado PM, Brandao RD, et al: Familial breast/ovarian cancer and BRCA1/2 genetic screening: The role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem 55:1105-1113, 2007
22. Abbott DW, Freeman ML, Holt JT: Doublestrand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Nat Cancer Inst 90:978-985, 1998
23. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-1120, 2008